Skip to main content
SpringerLink
Log in

Epidemiology of Diffuse Low-Grade Gliomas

  • Chapter
  • First Online:
Diffuse Low-Grade Gliomas in Adults

Abstract

Diffuse low-grade gliomas (DLGGs) belong to primary central nervous system tumors (PCNSTs) and include diffuse astrocytomas (fibrillary astrocytoma, gemistocytic astrocytoma, protoplasmic astrocytoma), oligodendroglioma, and oligoastrocytoma.

Specific epidemiological publications of DLGG are very rare. However, it is possible to obtain epidemiological data concerning DLGG by selecting some publications referring to all PCNSTs, gliomas, or even to low-grade gliomas (LGGs). (We will show that the term “LGG” is not well appropriate.).

This work summarizes the definitions and descriptive epidemiological data for DLGG and PCNST. DLGGs account for approximately 15 % of all gliomas, and incidence rate is about 1/100,000 person-years or just a little less. Main prognostic factors (e.g., age, performance status, location, volume and growth rate of the tumor, extent of surgical resection, histology) are discussed, and it is shown how they influence survival. Recent literature proposes a lot of new spontaneous prognostic factors, but until now, just a few are validated. In the other hand, little data are available to define best combinations of the different therapeutic strategies (successive surgeries, chemotherapy, radiotherapy, and new treatments).

This work proposes new efficient methodology to evaluate medical care and quality of life. The developments of modern informatics technology will revolutionize our methods of recording data. Collaboration between all medical specialties (including epidemiology and biostatistics) and development of large databases are the keys of efficiency for the future.

This chapter also summarizes knowledge of risk factors for DLGG and PCNST and proposes classical and new directions for searching etiologies for these tumors.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 159.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. WHO classification of tumours of the central nervous system. Lyon: International Agency for Research on Cancer; 2007.

    Google Scholar 

  2. Arora RS, Alston RD, Eden TOB, Estlin EJ, Moran A, Geraci M, et al. Are reported increases in incidence of primary CNS tumours real? An analysis of longitudinal trends in England, 1979–2003. Eur J Cancer. 2010;46:1607–16.

    Article  PubMed  Google Scholar 

  3. Bondy ML, Scheurer ME, Malmer B, Barnholtz-Sloan JS, Davis FG, Il’yasova D, et al. Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium. Cancer. 2008;113 Suppl 7:1953–68.

    Article  PubMed  Google Scholar 

  4. Kleihues P, Cavenee WK. Tumours of the nervous system pathology and genetics, World health classification of tumors. Lyon: International Agency for Research on Cancer; 2000.

    Google Scholar 

  5. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114:97–109.

    Article  PubMed  Google Scholar 

  6. McCarthy BJ, Surawicz T, Bruner JM, Kruchko C, Davis F. Consensus conference on brain tumor definition for registration. Neurooncology. 2002;4:134–45.

    Google Scholar 

  7. McCarthy BJ, Kruchko C. Central Brain Tumor Registry of United States. Consensus conference on cancer registration of brain and central nervous system tumors. Neurooncology. 2005;7:196–201.

    Google Scholar 

  8. Wrensch M, Minn Y, Chew T, Bondy M, Berger MS. Epidemiology of primary brain tumors: current concepts and review of the literature. Neurooncology. 2002;4:278–99.

    Google Scholar 

  9. Kohler BA, Ward E, McCarthy BJ, Schymura MJ, Ries LA, Eheman C, et al. Annual report to the nation on the status of cancer, 1975–2007, featuring tumors of the brain and other nervous system. J Natl Cancer Inst. 2011;103:714–36.

    Article  PubMed  Google Scholar 

  10. DeAngelis LM. Brain tumors. N Engl J Med. 2001;344:114–23.

    Article  PubMed  CAS  Google Scholar 

  11. Bauchet L, Rigau V, Mathieu-Daudé H, Figarella-Branger D, Hugues D, Palusseau L, et al. French brain tumor data bank: methodology and first results on 10,000 cases. J Neurooncol. 2007;84:189–99.

    Article  PubMed  Google Scholar 

  12. Bauchet L, Rigau V, Mathieu-Daudé H, Fabbro-Peray P, Palenzuela G, Figarella-Branger D, et al. Clinical epidemiology for childhood primary central nervous system tumors. J Neurooncol. 2009;92:87–98.

    Article  PubMed  Google Scholar 

  13. Wöhrer A, Waldhör T, Heinzl H, Hackl M, Feichtinger J, Gruber-Mösenbacher U, et al. The Austrian Brain Tumour Registry: a cooperative way to establish a population-based brain tumour registry. J Neurooncol. 2009;95:401–11.

    Article  PubMed  Google Scholar 

  14. CBTRUS. CBTRUS 2009–2010 eighteen states statistical report tables. Published by the Central Brain Tumor Registry of the United States, Hinsdale. 2009. Available at website: http://www.cbtrus.org/2007-2008/2007-2008.html. Accessed 17 Apr 2012.

  15. CBTRUS. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2004–2007. Published by the Central Brain Tumor Registry of the United States, Hinsdale. 2011. Available at website: http://www.cbtrus.org/2011-NPCR-SEER/WEB-0407-Report-3-3-2011.pdf Accessed 03 Mars 2011.

  16. CBTRUS. Central Brain Tumor Registry of the United States, statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2004–2008. 2012. http://www.cbtrus.org/2012-NPCR-SEER/CBTRUS_Report_2004-2008_3-23-2012.pdf. Accessed 17 Apr 2012.

  17. Rigau V, Zouaoui S, Mathieu-Daudé H, Darlix A, Maran A, Trétarre B, et al. French brain tumor ­database: 5-year histological results on 25 756 cases. Brain Pathol. 2011;21:633–44.

    Article  PubMed  Google Scholar 

  18. Baldi I, Gruber A, Alioum A, Berteaud E, Lebailly P, Huchet A, et al. Descriptive epidemiology of CNS tumors in France: results from the Gironde Registry for the period 2000–2007. Neuro Oncol. 2011;13:1370–8.

    Article  PubMed  CAS  Google Scholar 

  19. ENCR, European Network of Cancer Registries. Recommendations for coding tumours of the brain and central nervous system. Development and Recommendations on Cancer Registration and Standards/Working Groups: Tumours of the Brain and Central Nervous System crossed PDF link: English. Distributed in 1998. Available at: http://www.encr.com.fr. Accessed 17 Apr 2012.

  20. Fritz A, Percy C, Jack A, Shanmugaratnam K, Sobin L, Parkin DM, et al. International classification of diseases for oncology. 3rd ed. Geneva: World Health Organization; 2000.

    Google Scholar 

  21. Zouaoui S, Rigau V, Mathieu-Daudé H, Darlix A, Bessaoud F, Fabbro-Peray P, et al. French brain tumor database: general results on 40,000 cases, main current applications and future prospects. Neurochirurgie. 2012;58:4–13.

    Article  PubMed  CAS  Google Scholar 

  22. Hartmann C, Mueller W, von Deimling A. Pathology and molecular genetics of oligodendroglial tumors. J Mol Med. 2004;82:638–55.

    Article  PubMed  CAS  Google Scholar 

  23. McCarthy BJ, Propp JM, Davis FG, Burger PC. Time trends in oligodendroglial and astrocytic tumor incidence. Neuroepidemiology. 2008;30:34–44.

    Article  PubMed  Google Scholar 

  24. Daumas-Duport C, Beuvon F, Varlet P, Fallet-Bianco C. Gliomas: WHO and Sainte-Anne Hospital classifications. Ann Pathol. 2000;20:413–28.

    PubMed  CAS  Google Scholar 

  25. Mittler MA, Walters BC, Stopa EG. Observer reliability in histological grading of astrocytoma stereotactic biopsies. J Neurosurg. 1996;85:1091–4.

    Article  PubMed  CAS  Google Scholar 

  26. Ruiz J, Lesser GJ. Low-grade gliomas. Curr Treat Options Oncol. 2009;10:231–42.

    Article  PubMed  Google Scholar 

  27. Bristol RE. Low-grade glial tumors: are they all the same? Semin Pediatr Neurol. 2009;16:23–6.

    Article  PubMed  Google Scholar 

  28. Piepmeier JM. Current concepts in the evaluation and management of WHO grade II gliomas. J Neurooncol. 2009;92:253–9.

    Article  PubMed  Google Scholar 

  29. Claus EB, Black PM. Survival rates and patterns of care for patients diagnosed with supratentorial low-grade gliomas: data from the SEER program, 1973–2001. Cancer. 2006;106:1358–63.

    Article  PubMed  Google Scholar 

  30. Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta Neuropathol. 2005;109:93–108.

    Article  PubMed  Google Scholar 

  31. Okamoto Y, Di Patre PL, Burkhard C, Horstmann S, Jourde B, Fahey M, et al. Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas. Acta Neuropathol. 2004;108:49–56.

    Article  PubMed  Google Scholar 

  32. Nielsen MS, Christensen HC, Kosteljanetz M, Johansen C. Incidence of and survival from oligodendroglioma in Denmark, 1943–2002. Neuro Oncol. 2009;11:311–7.

    Article  PubMed  Google Scholar 

  33. Sant M, Minicozzi P, Lagorio S, Børge Johannesen T, Marcos-Gragera R, Francisci S, et al. Survival of European patients with central nervous system tumors. Int J Cancer. 2012;131(1):173–85.

    Article  PubMed  CAS  Google Scholar 

  34. Crocetti E, Trama A, Stiller C, Caldarella A, Soffietti R, Jaal J, et al. Epidemiology of glial and non-glial brain tumours in Europe. Eur J Cancer. 2012;48(10):1532–42.

    Article  PubMed  Google Scholar 

  35. Davis FG, Kupelian V, Freels S, McCarthy B, Surawicz T. Prevalence estimates for primary brain tumors in the United States by behavior and major histology groups. Neuro Oncol. 2001;3:152–8.

    PubMed  CAS  Google Scholar 

  36. Porter KR, McCarthy BJ, Freels S, Kim Y, Davis FG. Prevalence estimates for primary brain tumors in the United States by age, gender, behavior, and histology. Neuro Oncol. 2010;12:520–7.

    Article  PubMed  Google Scholar 

  37. Cook MB, Dawsey SM, Freedman ND, Inskip PD, Wichner SM, Quraishi SM, et al. Sex disparities in cancer incidence by period and age. Cancer Epidemiol Biomarkers Prev. 2009;18:1174–82.

    Article  PubMed  Google Scholar 

  38. Soffietti R, Baumert BG, Bello L, von Deimling A, Duffau H, Frénay M, et al. Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task Force. Eur J Neurol. 2010;17:1124–33.

    Article  PubMed  CAS  Google Scholar 

  39. Sanai N, Chang S, Berger MS. Low-grade gliomas in adults. J Neurosurg. 2011;115:948–65.

    Article  PubMed  Google Scholar 

  40. Loiseau H, Bousquet P, Rivel J, Vital C, Kantor G, Rougier A, et al. Supratentorial low-grade astrocytomas in adults. Prognostic factors and therapeutic indications. Apropos of a series of 141 patients. Neurochirurgie. 1995;41:38–50.

    PubMed  CAS  Google Scholar 

  41. Pignatti F, van den Bent M, Curran D, Debruyne C, Sylvester R, Therasse P, et al. Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol. 2002;20:2076–84.

    Article  PubMed  Google Scholar 

  42. van Veelen ML, Avezaat CJ, Kros JM, van Putten W, Vecht C. Supratentorial low grade astrocytoma: prognostic factors, dedifferentiation, and the issue of early versus late surgery. J Neurol Neurosurg Psychiatry. 1998;64:581–7.

    Article  PubMed  Google Scholar 

  43. Berger MS, Rostomily RC. Low grade gliomas: functional mapping resection strategies, extent of resection, and outcome. J Neurooncol. 1997;34:85–101.

    Article  PubMed  CAS  Google Scholar 

  44. Duffau H, Capelle L. Preferential brain locations of low-grade gliomas. Cancer. 2004;100:2622–6.

    Article  PubMed  Google Scholar 

  45. Pallud J, Mandonnet E, Duffau H, Kujas M, Guillevin R, Galanaud D, et al. Prognostic value of initial magnetic resonance imaging growth rates for World Health Organization grade II gliomas. Ann Neurol. 2006;60:380–3.

    Article  PubMed  Google Scholar 

  46. Rees J, Watt H, Jäger HR, Benton C, Tozer D, Tofts P, et al. Volumes and growth rates of untreated adult low-grade gliomas indicate risk of early malignant transformation. Eur J Radiol. 2009;72:54–64.

    Article  PubMed  Google Scholar 

  47. Mandonnet E, Delattre JY, Tanguy ML, Swanson KR, Carpentier AF, Duffau H, et al. Continuous growth of mean tumor diameter in a subset of grade II gliomas. Ann Neurol. 2003;53:524–8.

    Article  PubMed  Google Scholar 

  48. Mandonnet E, Pallud J, Fontaine D, Taillandier L, Bauchet L, Peruzzi P, et al. Inter- and intrapatients comparison of WHO grade II glioma kinetics before and after surgical resection. Neurosurg Rev. 2010;33:91–6.

    Article  PubMed  Google Scholar 

  49. Bauman G, Lote K, Larson D, Stalpers L, Leighton C, Fisher B, et al. Pretreatment factors predict overall survival for patients with low-grade glioma: a recursive partitioning analysis. Int J Radiat Oncol Biol Phys. 1999;45:923–9.

    Article  PubMed  CAS  Google Scholar 

  50. Chang EF, Smith JS, Chang SM, Lamborn KR, Prados MD, Butowski N, et al. Preoperative prognostic classification system for hemispheric low-grade gliomas in adults. J Neurosurg. 2008;109:817–24.

    Article  PubMed  Google Scholar 

  51. Chang EF, Clark A, Jensen RL, Bernstein M, Guha A, Carrabba G, et al. Multiinstitutional validation of the University of California at San Francisco low-grade glioma prognostic scoring system. J Neurosurg. 2009;111:203–10.

    Article  PubMed  Google Scholar 

  52. Smith JS, Chang EF, Lamborn KR, Chang SM, Prados MD, Cha S, et al. Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J Clin Oncol. 2008;26:1338–45.

    Article  PubMed  Google Scholar 

  53. van den Bent MJ, Afra D, de Witte O, Ben Hassel M, Schraub S, Hoang-Xuan K, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet. 2005;366:985–90.

    Article  PubMed  Google Scholar 

  54. Blonski M, Taillandier L, Herbet G, Maldonado IL, Beauchesne P, Fabbro M, et al. Combination of neoadjuvant chemotherapy followed by surgical resection as a new strategy for WHO grade II gliomas: a study of cognitive status and quality of life. J Neurooncol. 2012;106:353–66.

    Article  PubMed  CAS  Google Scholar 

  55. van den Bent MJ, Wefel JS, Schiff D, Taphoorn MJ, Jaeckle K, Junck L, et al. Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol. 2011;12:583–93.

    Article  PubMed  Google Scholar 

  56. McGirt MJ, Chaichana KL, Attenello FJ, Weingart JD, Than K, Burger PC, et al. Extent of surgical resection is independently associated with survival in patients with hemispheric infiltrating low-grade gliomas. Neurosurgery. 2008;63:700–7.

    Article  PubMed  Google Scholar 

  57. Bauchet L, Mathieu-Daudé H, Fabbro-Peray P, Rigau V, Fabbro M, Chinot O, et al. Oncological patterns of care and outcome for 952 patients with newly diagnosed glioblastoma in 2004. Neuro Oncol. 2010;12:725–35.

    Article  PubMed  Google Scholar 

  58. Woehrer A, Slavc I, Waldhoer T, Heinzl H, Zielonke N, Czech T, et al. Incidence of atypical teratoid/rhabdoid tumors in children: a population-based study by the Austrian Brain Tumor Registry, 1996–2006. Cancer. 2010;116:5725–32.

    Article  PubMed  Google Scholar 

  59. NCCN Guidelines. Central nervous system cancer. Version 1. 2012. http://www.nccn.org/professionals/physician_gls/pdf/cns.pdf. Accessed 17 Apr 2012.

  60. McCarthy BJ, Rankin KM, Aldape K, Bondy ML, Brännström T, Broholm H, et al. Risk factors for oligodendroglial tumors: a pooled international study. Neuro Oncol. 2011;13:242–50.

    Article  PubMed  Google Scholar 

  61. Gozé C, Bezzina C, Gozé E, Rigau V, Maudelonde T, Bauchet L, et al. 1P19Q loss but not IDH1 mutations influences WHO grade II gliomas spontaneous growth. J Neurooncol. 2012;108(1):69–75.

    Article  PubMed  Google Scholar 

  62. Bettegowda C, Agrawal N, Jiao Y, Sausen M, Wood LD, Hruban RH, et al. Mutations in CIC and FUBP1 contribute to human oligodendroglioma. Science. 2011;333:1453–5.

    Article  PubMed  CAS  Google Scholar 

  63. Kim YH, Nobusawa S, Mittelbronn M, Paulus W, Brokinkel B, et al. Molecular classification of low-grade diffuse gliomas. Am J Pathol. 2010;177:2708–14.

    Article  PubMed  Google Scholar 

  64. Ohgaki H, Kleihues P. Genetic profile of astrocytic and oligodendroglial gliomas. Brain Tumor Pathol. 2011;28:177–83.

    Article  PubMed  CAS  Google Scholar 

  65. Ohgaki H, Kim YH, Steinbach JP. Nervous system tumors associated with familial tumor syndromes. Curr Opin Neurol. 2010;23:583–91.

    Article  PubMed  CAS  Google Scholar 

  66. Kyritsis AP, Bondy ML, Rao JS, Sioka C. Inherited predisposition to glioma. Neuro Oncol. 2010;12:104–13.

    Article  PubMed  CAS  Google Scholar 

  67. Ron E, Modan B, Boice Jr JD, Alfandary E, Stovall M, Chetrit A, et al. Tumors of the brain and nervous system after radiotherapy in childhood. N Engl J Med. 1988;319:1033–9.

    Article  PubMed  CAS  Google Scholar 

  68. Yonehara S, Brenner AV, Kishikawa M, Inskip PD, Preston DL, Ron E, et al. Clinical and epidemiologic characteristics of first primary tumors of the central nervous system and related organs among atomic bomb survivors in Hiroshima and Nagasaki, 1958–1995. Cancer. 2004;101:1644–54.

    Article  PubMed  Google Scholar 

  69. Hemminki K, Tretli S, Sundquist J, Johannesen TB, Granström C. Familial risks in nervous-system tumours: a histology-specific analysis from Sweden and Norway. Lancet Oncol. 2009;10:481–8.

    Article  PubMed  Google Scholar 

  70. Inskip PD, Hoover RN, Devesa SS. Brain cancer incidence trends in relation to cellular telephone use in the United States. Neuro Oncol. 2010;12:1147–51.

    Article  PubMed  Google Scholar 

  71. INTERPHONE Study Group. Brain tumour risk in relation to mobile telephone use: results of the INTERPHONE international case-control study. Int J Epidemiol. 2010;39:675–94.

    Article  Google Scholar 

  72. Deltour I, Auvinen A, Feychting M, Johansen C, Klaeboe L, Sankila R, et al. Mobile phone use and incidence of glioma in the Nordic countries 1979–2008: consistency check. Epidemiology. 2012;23:301–7.

    Article  PubMed  Google Scholar 

  73. Terry MB, Howe G, Pogoda JM, Zhang FF, Ahlbom A, Choi W, et al. An international case-control study of adult diet and brain tumor risk: a histology-specific analysis by food group. Ann Epidemiol. 2009;19:161–71.

    Article  PubMed  Google Scholar 

  74. Sheweita SA, Sheikh BY. Can dietary antioxidants reduce the incidence of brain tumors? Curr Drug Metab. 2011;12:587–93.

    PubMed  CAS  Google Scholar 

  75. Scheurer ME, El-Zein R, Thompson PA, Aldape KD, Levin VA, Gilbert MR, et al. Long-term anti-inflammatory and antihistamine medication use and adult glioma risk. Cancer Epidemiol Biomarkers Prev. 2008;17:1277–81.

    Article  PubMed  CAS  Google Scholar 

  76. Ferris J, McCoy L, Neugut AI, Wrensch M, Lai R. HMG CoA reductase inhibitors, NSAIDs and risk of glioma. Int J Cancer. 2012;131(6):E1031–7.

    Article  PubMed  CAS  Google Scholar 

  77. Samanic CM, De Roos AJ, Stewart PA, Rajaraman P, Waters MA, Inskip PD. Occupational exposure to pesticides and risk of adult brain tumors. Am J Epidemiol. 2008;167:976–85.

    Article  PubMed  Google Scholar 

  78. Provost D, Cantagrel A, Lebailly P, Jaffré A, Loyant V, Loiseau H, et al. Brain tumours and exposure to pesticides: a case-control study in southwestern France. Occup Environ Med. 2007;64:509–14.

    Article  PubMed  CAS  Google Scholar 

  79. Vinson F, Merhi M, Baldi I, Raynal H, Gamet-Payrastre L. Exposure to pesticides and risk of ­childhood cancer: a meta-analysis of recent epidemiological studies. Occup Environ Med. 2011;68:694–702.

    Article  PubMed  CAS  Google Scholar 

  80. Felini MJ, Olshan AF, Schroeder JC, Carozza SE, Miike R, Rice T, et al. Reproductive factors and hormone use and risk of adult gliomas. Cancer Causes Control. 2009;20:87–96.

    Article  PubMed  Google Scholar 

  81. Benson VS, Pirie K, Green J, Casabonne D, Beral V, Million Women Study Collaborators. Lifestyle factors and primary glioma and meningioma tumours in the Million Women Study cohort. Br J Cancer. 2008;99:185–90.

    Article  PubMed  CAS  Google Scholar 

  82. Schlehofer B, Hettinger I, Ryan P, Blettner M, Preston-Martin S, Little J, et al. Occupational risk factors for low grade and high grade glioma: results from an international case control study of adult brain tumours. Int J Cancer. 2005;113:116–25.

    Article  PubMed  CAS  Google Scholar 

  83. Scheurer ME, Etzel CJ, Liu M, Barnholtz-Sloan J, Wiklund F, Tavelin B, et al. Familial aggregation of glioma: a pooled analysis. Am J Epidemiol. 2010;172:1099–107.

    Article  PubMed  Google Scholar 

  84. Brain Tumor Epidemiology Consortium (BTEC). Available at website: http://epi.grants.cancer.gov/btec/. Accessed 17 Apr 2012.

  85. Gu J, Liu Y, Kyritsis AP, Bondy ML. Molecular epidemiology of primary brain tumors. Neurotherapeutics. 2009;6:427–35.

    Article  PubMed  CAS  Google Scholar 

  86. GLIOGENE. An international brain tumor family study. Available at website: http://www.gliogene.org/. Accessed 17 Apr 2012.

  87. Shete S, Hosking FJ, Robertson LB, Dobbins SE, Sanson M, Malmer B, et al. Genome-wide association study identifies five susceptibility loci for glioma. Nat Genet. 2009;41:899–904.

    Article  PubMed  CAS  Google Scholar 

  88. Wrensch M, Jenkins RB, Chang JS, Yeh RF, Xiao Y, Decker PA, et al. Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility. Nat Genet. 2009;41:905–8.

    Article  PubMed  CAS  Google Scholar 

  89. Jenkins RB, Wrensch MR, Johnson D, Fridley BL, Decker PA, Xiao Y, et al. Distinct germ line polymorphisms underlie glioma morphologic heterogeneity. Cancer Genet. 2011;204:13–8.

    Article  PubMed  Google Scholar 

  90. Yan H, Bigner DD, Velculescu V, Parsons DW. Mutant metabolic enzymes are at the origin of gliomas. Cancer Res. 2009;69:9157–9.

    Article  PubMed  CAS  Google Scholar 

  91. Watanabe T, Nobusawa S, Kleihues P, Ohgaki H. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol. 2009;174:1149–53.

    Article  PubMed  CAS  Google Scholar 

  92. Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, et al. Identification of a CpG island methylator phenotype that defines a ­distinct subgroup of glioma. Cancer Cell. 2010;17:510–22.

    Article  PubMed  CAS  Google Scholar 

  93. Berntsson SG, Wibom C, Sjöström S, Henriksson R, Brännström T, Broholm H, et al. Analysis of DNA repair gene polymorphisms and survival in low-grade and anaplastic gliomas. J Neurooncol. 2011;105:531–8.

    Article  PubMed  CAS  Google Scholar 

  94. Melin B. Genetic causes of glioma: new leads in the labyrinth. Curr Opin Oncol. 2011;23:643–7.

    Article  PubMed  Google Scholar 

  95. Duffau H. Surgery of low-grade gliomas: towards a « functional neurooncology ». Curr Opin Oncol. 2009;21:543–9.

    Article  PubMed  Google Scholar 

  96. Duffau H, Pallud J, Mandonnet E. Evidence for the genesis of WHO grade II glioma in an asymptomatic young adult using repeated MRIs. Acta Neurochir (Wien). 2011;153:473–7.

    Article  Google Scholar 

  97. Pallud J, Fontaine D, Duffau H, Mandonnet E, Sanai N, Taillandier L, et al. Natural history of incidental World Health Organization grade II gliomas. Ann Neurol. 2010;68:727–33.

    Article  PubMed  Google Scholar 

  98. Gerin C, Pallud J, Grammaticos B, Mandonnet E, Deroulers C, Varlet P, et al. Improving the time-­machine: estimating date of birth of grade II gliomas. Cell Prolif. 2012;45:76–90.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurosurgery, Hôpital Gui de Chauliac, Centre Hospitalier Universitaire, 80 avenue Augustin Fliche, 34295, Montpellier, France

    Luc Bauchet MD, PhD

  2. INSERM U1051, Institut des Neurosciences, Montpellier, France

    Luc Bauchet MD, PhD

  3. French Brain Tumor DataBase, Groupe de Neuro-Oncologie du Languedoc-Roussillon, Registre des Tumeurs de l’Hérault, Centre de Lutte Contre le Cancer Val d’Aurelle, Montpellier, France

    Luc Bauchet MD, PhD

Authors
  1. Luc Bauchet MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Luc Bauchet MD, PhD .

Editor information

Editors and Affiliations

  1. , INSERM U1051, Institute for Neurosciences of Montpelli, av. Augustin Fliche 80, Montpellier, 34295, France

    Hugues Duffau

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer-Verlag London

About this chapter

Cite this chapter

Bauchet, L. (2013). Epidemiology of Diffuse Low-Grade Gliomas. In: Duffau, H. (eds) Diffuse Low-Grade Gliomas in Adults. Springer, London. https://doi.org/10.1007/978-1-4471-2213-5_2

Download citation

  • DOI: https://doi.org/10.1007/978-1-4471-2213-5_2

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-4471-2212-8

  • Online ISBN: 978-1-4471-2213-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation